Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded to Buy Rating by Wall Street Zen

Wall Street Zen cut shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a strong-buy rating to a buy rating in a report issued on Saturday morning,Wall Street Zen reports.

REGN has been the subject of several other research reports. Royal Bank Of Canada upped their target price on shares of Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the stock a “sector perform” rating in a research report on Friday, July 31st. BMO Capital Markets cut their price target on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. Piper Sandler decreased their price objective on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a report on Thursday, July 9th. Finally, Wells Fargo & Company increased their price objective on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a report on Friday, July 31st. Fourteen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $802.18.

Regeneron Pharmaceuticals Trading Down 1.5%

Shares of NASDAQ REGN opened at $781.49 on Friday. Regeneron Pharmaceuticals has a 12-month low of $541.00 and a 12-month high of $859.34. The company has a market cap of $80.46 billion, a price-to-earnings ratio of 19.32, a price-to-earnings-growth ratio of 1.53 and a beta of 0.20. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The stock’s 50 day simple moving average is $754.93 and its 200 day simple moving average is $720.58.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. During the same period in the prior year, the business earned $12.81 EPS. The firm’s revenue was up 16.7% on a year-over-year basis. Equities research analysts expect that Regeneron Pharmaceuticals will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were paid a dividend of $0.94 per share. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.29%.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,131 shares of the business’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $857.39, for a total transaction of $969,708.09. Following the sale, the executive vice president directly owned 12,003 shares in the company, valued at approximately $10,291,252.17. The trade was a 8.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur Ryan sold 200 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 4,146 shares of company stock valued at $3,432,488 over the last quarter. Corporate insiders own 6.97% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Orbimed Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at $11,358,000. Lockheed Martin Investment Management Co. acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth $2,702,000. BlackRock Inc. acquired a new position in Regeneron Pharmaceuticals during the second quarter worth $5,682,636,000. National Pension Service lifted its holdings in shares of Regeneron Pharmaceuticals by 29.8% during the fourth quarter. National Pension Service now owns 360,988 shares of the biopharmaceutical company’s stock valued at $278,636,000 after acquiring an additional 82,853 shares during the period. Finally, Eurizon Capital SGR S.p.A. bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at $10,472,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: RBC said Regeneron is increasingly likely to retain key patent protection for Eylea HD, a major commercial product. Preserving exclusivity could help protect revenue and earnings from biosimilar competition. Regeneron Pharmaceuticals More Likely to Retain Eylea HD Patent, RBC Says
• Positive Sentiment: HSBC raised its price target on REGN to $920 from $800 and maintained a Buy rating, implying substantial upside from the referenced share price. The move signals improved confidence in Regeneron’s outlook. HSBC Raises Regeneron Price Target
• Neutral Sentiment: A reported September short-interest figure of zero shares is not actionable because it is inconsistent with normal market data and produces a zero-day short-interest ratio.
• Negative Sentiment: Multiple law firms are promoting a securities class action against Regeneron, with a September 14 deadline for investors to seek lead-plaintiff status. The repeated notices add reputational and potential legal-cost risks, although they largely repeat the same lawsuit information rather than announce a new development. Regeneron Investor Deadline and Class Action Lawsuit
• Negative Sentiment: The lawsuit stems from the failure of a Phase 3 melanoma trial involving the Fianlimab-Libtayo therapy and allegations that Regeneron minimized statistical and protocol risks, including issues affecting progression-free-survival analysis. The trial failure reportedly erased about $11 billion in market value and raises concerns about the company’s pipeline and disclosure practices. Regeneron Clinical-Trial Risk Disclosure Lawsuit

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.

Regeneron’s marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.